Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research

Contract Research

TES Pharma and EPFL establish R&D collaboration TES Pharma and École Polytechnique Fédérale de Lausanne (EPFL) has formed new research and development collaboration on novel small molecule modulators of the kynurenine pathway as therapies for metabolic disorders and age-related diseases.
Contract Research & Services > Contract Research > News
Neothetics to evaluate clinical effect of LIPO-202 to reduce central abdominal bulging By PBR Staff Writer
Neothetics has started the post-treatment safety and duration of effect study, LIPO-202-CL-23, of the first non-invasive injectable drug candidate 'LIPO-202' to reduce central abdominal bulging due to subcutaneous fat in non-obese subjects.
Contract Research & Services > Contract Research > News Oramed begins patient enrollment in Phase IIb oral insulin trial of ORMD-0801 By PBR Staff Writer
Israel-based Oramed Pharmaceuticals has enrolled the first patient in its Phase IIb of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes.
Contract Research & Services > Contract Research > News
See more Contract Research news

Latest Contract Research News and Insight

View all Contract Research news or find news targeted to your interests
Immunocore enters into immunotherapy-based clinical trial collaboration with Lilly
By PBR Staff Writer
Immunocore has entered into immunotherapy-based clinical trial collaboration with Eli Lilly and Company to explore the use of its IMCgp100 in combination with galunisertib and merestinib to treat melanoma.
Contract Research & Services > Contract Research > News
Vitae starts Phase I single ascending dose study of VTP-43742 in autoimmune disorders
Vitae Pharmaceuticals (VTAE), a clinical-stage biotechnology company, announced the initiation of a Phase 1 single ascending dose clinical trial of VTP-43742, the company's wholly owned and potential first-in-class RORγt inhibitor for the treatment of autoimmune disorders, including psoriasis, multiple sclerosis, and various arthropathies, as well as rare and orphan disorders.
Contract Research & Services > Contract Research > News
Evaluation of the BioFlo® 320 Process Capabilities
| By Eppendorf
This poster characterizes the capabilities of the BioFlo320 in terms of key process parameters including oxygen transfer rate (OTR), volumetric mass transfer coecient (kLa), tip speed, mixing time, and water consumption. These data enable quantitative analyses of bioprocess engineering parameters, thus allowing potential users to gain insight into the system’s cell culture and fermentation capabilities.
Contract Research & Services > Contract Research > White Papers
Taking the Strain
| By Eppendorf
Today, the rapidly expanding demand for vaccine products for viral diseases such as rabies has necessitated the development of more sophisticated production techniques based around cell culture systems. This article reviews vaccine production strategies, with a focus on rabies, looking specifically at the use of the Vero cell line - used worldwide and approved by the US Food and Drug Administration - as well as media technology and the bioreactor options available.
Contract Research & Services > Contract Research > White Papers
WCCT Global gets large investment from Asian Equity Firm
WCCT Global, a full service contract research organization headquartered in Southern California, announced today a sizable investment from Asian private equity firm Medivate Partners.
Contract Research & Services > Contract Research > News
PRA Named Clinical Company of the Year
PRA Health Sciences (PRA) is pleased to announce that it was once again recognized as the Best Clinical Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Cary, North Carolina. This award follows PRA’s recognition as the Best International Clinical Company of the Year which was announced earlier this year in London.
Contract Research & Services > Contract Research > Press Releases
PRA Continues the Transformation of Clinical Trials with Predictivv
PRA Health Sciences, a leading global contract research organization, today announced its new Predictivv™ platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development. The Predictivv™ platform will be a fully integrated solution for designing, planning and optimizing the management of global clinical studies. Designed around a unified platform that harmonizes data, processes, and people across every aspect of a clinical study, Predictivv™ will enable unprecedented adaptive intelligence and decision support for the ever-increasing complexities of the clinical development process.
Contract Research & Services > Contract Research > Press Releases
Bristol-Myers expands R&D presence with new research site in Cambridge, US
Bristol-Myers Squibb Company announced important next steps in the evolution of the company’s R&D organization, including plans to expand its presence within hubs of scientific excellence and innovation with the opening of a new state-of-the-art research site in Cambridge, Mass. in addition to the ongoing expansion of the company’s R&D Discovery site in the San Francisco Bay Area.
Contract Research & Services > Contract Research > News
Columbia Care enters into agreement with Mount Sinai to drive Medical Marijuana Research
Columbia Care, one of the nation's leading medical marijuana companies, announced a research agreement today with the Icahn School of Medicine at Mount Sinai, an internationally acclaimed research institution in New York City, to advance the science and safe practice of medical marijuana therapy.
Contract Research & Services > Contract Research > News
AOBiome begins Phase II trial of AOB-based therapeutic for acne vulgaris
By PBR Staff Writer
AOBiome has started a Phase II clinical trial of a therapeutic product candidate, B244, based on its proprietary ammonia oxidizing bacteria (AOB) to treat mild to moderate acne vulgaris.
Contract Research & Services > Contract Research > News
View all Contract Research news or find news targeted to your interests